SG46451A1 - Detection and treatment of infections with immunoconjugates - Google Patents

Detection and treatment of infections with immunoconjugates

Info

Publication number
SG46451A1
SG46451A1 SG1996004773A SG1996004773A SG46451A1 SG 46451 A1 SG46451 A1 SG 46451A1 SG 1996004773 A SG1996004773 A SG 1996004773A SG 1996004773 A SG1996004773 A SG 1996004773A SG 46451 A1 SG46451 A1 SG 46451A1
Authority
SG
Singapore
Prior art keywords
antibody
pathogen
diagnostic
focus
composite
Prior art date
Application number
SG1996004773A
Other languages
English (en)
Inventor
David M Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of SG46451A1 publication Critical patent/SG46451A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG1996004773A 1989-08-24 1990-08-24 Detection and treatment of infections with immunoconjugates SG46451A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39956689A 1989-08-24 1989-08-24

Publications (1)

Publication Number Publication Date
SG46451A1 true SG46451A1 (en) 1998-02-20

Family

ID=23580041

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004773A SG46451A1 (en) 1989-08-24 1990-08-24 Detection and treatment of infections with immunoconjugates

Country Status (13)

Country Link
EP (1) EP0417927B1 (fr)
JP (1) JPH07121880B2 (fr)
KR (1) KR0179953B1 (fr)
AT (1) ATE151994T1 (fr)
AU (1) AU636172B2 (fr)
CA (1) CA1339415C (fr)
DE (1) DE69030545T2 (fr)
ES (1) ES2100164T3 (fr)
IE (1) IE903071A1 (fr)
IL (1) IL95457A (fr)
SG (1) SG46451A1 (fr)
WO (1) WO1991002541A1 (fr)
ZA (1) ZA906703B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
CA2065658A1 (fr) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugues de liposomes ou microbilles et anticorps specifiques pour les lymphocytes t et leur utilisation in vivo en tant que modulateurs de l'immunite
GB9517758D0 (en) * 1995-08-31 1995-11-01 Imutran Ltd Compositions and their uses
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
JP2002519334A (ja) * 1998-06-29 2002-07-02 ベルクター，ヴォルフガンク αエミッタとβエミッタとを主成分とする抗ウイルスおよび抗レトロウイルス放射免疫薬剤
CA2475247C (fr) * 2002-02-07 2015-08-04 Massachusetts Institute Of Technology Traitements anti-pathogenes
EP1419786A1 (fr) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Méthode pour sélectivement et quantitativement fonctionnaliser des fragments Fab d'immunoglobuline, molécules conjuguées utilisant ceux-ci et ses compositions
JP4928964B2 (ja) 2007-01-30 2012-05-09 本田技研工業株式会社 車両のスイングアーム式懸架装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3173342D1 (en) * 1980-03-03 1986-02-13 Milton David Goldenberg Agent for tumor localization and therapy with labeled antibodies and antibody fragments
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (fr) * 1982-03-09 1986-04-15 Thomas J. Mckearn Conjugats d'anticorps
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
EP0149709B2 (fr) * 1983-07-29 1995-11-29 Milton David Goldenberg Procédé pour augmenter la spécificité de cible dans la localisation d'anticorps et pour écarter les facteurs diagnostiques et thérapeutiques non-cible-spécifiques
US4855227A (en) * 1985-06-07 1989-08-08 Institute For Medical Research Rapid detection of mycoplasmas
US4894227A (en) * 1986-08-01 1990-01-16 Cetus Corporation Composition of immunotoxins with interleukin-2
US4932412A (en) * 1986-12-18 1990-06-12 Immunomedics, Inc. Intraoperative and endoscopic tumor detection and therapy
ATE122237T1 (de) * 1987-05-29 1995-05-15 Tanox Biosystems Inc Hiv-1 neutralisierende monoklonale antikörper.
CA1329119C (fr) * 1988-03-29 1994-05-03 Milton David Goldenberg Therapie faisant appel a des agents cytotoxiques
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions

Also Published As

Publication number Publication date
EP0417927A1 (fr) 1991-03-20
DE69030545T2 (de) 1997-08-07
AU636172B2 (en) 1993-04-22
DE69030545D1 (de) 1997-05-28
ZA906703B (en) 1991-06-26
EP0417927B1 (fr) 1997-04-23
JPH04506217A (ja) 1992-10-29
ES2100164T3 (es) 1997-06-16
KR0179953B1 (ko) 1999-03-20
IE903071A1 (en) 1991-02-27
AU6408290A (en) 1991-04-03
ATE151994T1 (de) 1997-05-15
IL95457A0 (en) 1991-06-30
WO1991002541A1 (fr) 1991-03-07
CA1339415C (fr) 1997-09-02
KR920700686A (ko) 1992-08-10
JPH07121880B2 (ja) 1995-12-25
IL95457A (en) 1997-01-10

Similar Documents

Publication Publication Date Title
RU96101193A (ru) Фрагменты антител в терапии
DK79390A (da) Anti-leukocytkonjugat og anvendelse heraf
SG46451A1 (en) Detection and treatment of infections with immunoconjugates
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
DE68928946T2 (de) Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
GR3024051T3 (en) Methods and compositions for the use of HIV env polypeptides and antibodies thereto
BR9007702A (pt) Metodo de tratamento
Fischel et al. The role of tubercle bacilli in adjuvant emulsions on antibody production to egg albumin
ATE407149T1 (de) Detoxifizierung durch intramuskulär verabreichte f(ab')2 fragmente
ATE408418T1 (de) Methoden zur inhibition von hiv-assoziierten krankheiten mittels monoklonaler antikörper gegen sich selbstgerichtete zytotoxische t-zellen
ATE111485T1 (de) Peptidbehandlung von hartnäckigen infektionskrankheiten.
Moroz Vipera palaestinae antivenin
WO1997035884A8 (fr) Production amelioree d'anticorps par l'utilisation de complexes antigene-anticorps
ES2013665A6 (es) Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso.
Zampachova Possibilities of serological evidence of sexually transmitted infection caused by Chlamydia trachomatis.
CA2079230A1 (fr) Antagonistes bcrf1 pour le traitement des infections dues au virus epstein-barr
RU99103391A (ru) Способ получения гипериммунной сыворотки против рожи свиней